SFA
EIGR

Sequoia Financial Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Sequoia Financial Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,100
Closed -$14.1K – 1309
2023
Q4 		$14.1K Hold
2,100
– – ﹤0.01% 1195
2023
Q3 		$19.2K Hold
2,100
– – ﹤0.01% 959
2023
Q2 		$44.4K Buy
+2,100
New +$64.7K ﹤0.01% 950

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Sequoia Financial Advisors's EIGR Position: Q1 2024 in Review

Sequoia Financial Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 2,100 shares — an estimated $14.1K sold.

Sequoia Financial Advisors first reported a position in EIGR in Q2 2023 and held it in 3 quarters. The position peaked at $44.4K in Q2 2023. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Sequoia Financial Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Sequoia Financial Advisors sold 2,100 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $14.1K.
  • Sequoia Financial Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2023 and held it in 3 quarters.
  • Sequoia Financial Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $44.4K in Q2 2023.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Sequoia Financial Advisors's 13F filing for Q1 2024, filed 30 Apr 2024.